DILUZIO, WILLOW,威洛．迪尔卢兹奥,威洛．迪爾盧茲奧,TRUONG, NOBEL T.,诺贝尔．T．张,諾貝爾．T．張,VARGA, CSANAD M.,乔纳德．M．沃尔高,喬納德．M．沃爾高,PALANIAPPAN, VAITHIANATHAN,维斯阿纳桑．帕拉尼阿帕安,維斯阿納桑．帕拉尼阿帕安,BROWN, JASON,杰森．布朗,FOX, IRVING H,欧文．H,威洛.迪尔卢兹奥,威洛.迪爾盧茲奧,诺贝尔.T.张,諾貝爾.T.張,乔纳德.M.沃尔高,喬納德.M.沃爾高,维斯阿纳桑.帕拉尼阿帕安,維斯阿納桑.帕拉尼阿帕安,杰森.布朗,欧文.H
申请号：
MOJ003004
公开号：
MOJ003004B
申请日:
2018.03.19
申请国别(地区):
MO
年份:
2018
代理人:
摘要：
The antibody preparation of mixture of the present invention description comprising non-reducing sugar, 4 β of anti alpha, 7 antibody and at least one amino acid. There is disclosed preparation the stability improved, the aggregation of reduction to be formed, and can postpone the wherein degradation of 4 β of anti alpha, 7 antibody or show any combination of these characteristics. The safe administration scheme of 4 β of the anti alpha, 7 antibody of therapeutically effective amount is followed and generated in vivo the present invention further provides a kind of easy what of these antibody preparations.本發明描述包含非還原糖、抗α4β7抗體和至少一種氨基酸的混合物的抗體製劑。公開的製劑具有提高的穩定性、减少的聚集體形成，且可延遲其中抗α4β7抗體的降解或展現這些特性的任何組合。本發明進一步提供這些抗體製劑的一種易於遵循且在體內産生治療有效量的所述抗α4β7抗體的安全給藥方案。
